Core Viewpoint - Company has received approval from the National Medical Products Administration for clinical trials of HRS9531 and HRS-5817 injection solutions, which are expected to enhance its product pipeline in the obesity treatment market [1][2] Group 1: HRS9531 Injection - HRS9531 is a novel dual agonist targeting GLP-1R and GIPR, designed to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, thereby improving blood sugar levels and aiding weight loss [1] - The global sales forecast for ZEPBOUND, a similar drug by Eli Lilly, is approximately $4.926 billion for 2024, indicating a significant market opportunity for HRS9531 [1] - Cumulative R&D investment for HRS9531 has reached approximately 51.854 million yuan [1] Group 2: HRS-5817 Injection - HRS-5817 is a self-developed Class 1 chemical drug, showing weight loss effects in preclinical studies on obese animal models with good safety profiles [2] - Currently, there are no approved drugs targeting the same receptor as HRS-5817 in both domestic and international markets, highlighting its potential uniqueness [2] - Cumulative R&D investment for HRS-5817 has reached approximately 2.489 million yuan [2]